Antibody‐Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review

2021 ◽  
Author(s):  
Hananeh Baradaran ◽  
Simin Dashti‐Khavidaki ◽  
Mohammad Taher ◽  
Monavar Talebian ◽  
Mohsen Nasiri‐Toosi ◽  
...  
Keyword(s):  
Literature Review ◽  
Liver Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Adult Liver ◽  
Antibody Mediated Rejection ◽  
Liver Transplant Recipients

Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature

2016 ◽  
Vol 21 (1) ◽  
pp. e12791 ◽  
Author(s):  
Laura J. Wozniak ◽  
Bita V. Naini ◽  
Michelle J. Hickey ◽  
Sarathi Bhattacharyya ◽  
Elaine F. Reed ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Review Of The Literature ◽  
Antibody Mediated Rejection ◽  
Pediatric Liver ◽  
Liver Transplant Recipients ◽  
Pediatric Liver Transplant

scholarly journals Prevalence of prednisolone (non)compliance in adult liver transplant recipients

2005 ◽  
Vol 18 (8) ◽  
pp. 960-966 ◽  
Author(s):  
Gerda Drent ◽  
Elizabeth B. Haagsma ◽  
Sabina De Geest ◽  
Aad P. van den Berg ◽  
Els M. Ten Vergert ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Transplant Recipients ◽  
Adult Liver ◽  
Liver Transplant Recipients

Klebsiellanecrotizing soft tissue infections in liver transplant recipients: a case series

2013 ◽  
Vol 15 (4) ◽  
pp. E157-E163 ◽  
Author(s):  
M.M. Rana ◽  
M. Sturdevant ◽  
G. Patel ◽  
S. Huprikar
Keyword(s):  
Soft Tissue ◽  
Liver Transplant ◽  
Case Series ◽  
Soft Tissue Infections ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Treatment of Candida infections with fluconazole in adult liver transplant recipients: Is TDM‐guided dosing adaptation helpful?

2019 ◽  
Vol 21 (4) ◽  
Author(s):  
Elda Righi ◽  
Alessia Carnelutti ◽  
Umberto Baccarani ◽  
Assunta Sartor ◽  
Piergiorgio Cojutti ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Transplant Recipients ◽  
Adult Liver ◽  
Candida Infections ◽  
Liver Transplant Recipients

Clinical Outcomes of Pneumocystis carinii Pneumonia in Adult Liver Transplant Recipients

2013 ◽  
Vol 45 (8) ◽  
pp. 3057-3060 ◽  
Author(s):  
Y.-I. Choi ◽  
S. Hwang ◽  
G.-C. Park ◽  
J.-M. Namgoong ◽  
D.-H. Jung ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Clinical Outcomes ◽  
Pneumocystis Carinii Pneumonia ◽  
Pneumocystis Carinii ◽  
Transplant Recipients ◽  
Adult Liver ◽  
Liver Transplant Recipients

Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients

2019 ◽  
Vol 54 (7) ◽  
pp. 652-661 ◽  
Author(s):  
Jia Shao ◽  
Chenyu Wang ◽  
Peng Fu ◽  
Fan Chen ◽  
Yi Zhang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Distribution Volume ◽  
Therapeutic Window ◽  
Population Pharmacokinetic ◽  
Transplant Recipients ◽  
Adult Liver ◽  
Chinese Adult ◽  
Starting Dose ◽  
Liver Transplant Recipients

Background: Tacrolimus (TAC) is widely used after liver transplantation, but the therapeutic window is narrow. Objective: The purpose was to study both donor and recipient CYP3A5*3 genotypes affecting TAC apparent clearance rate (CL/F) and investigate a TAC population pharmacokinetic (PPK) model in Chinese liver transplant recipients for potential starting-dose individualized medication. Methods: A data set of 721 TAC concentrations was obtained from 43 adult liver transplant recipients. The TAC PPK model was analyzed using nonlinear mixed-effects modeling. Potential covariates, including demographic characteristics, physiological and pathological data, concomitant medications, and CYP3A5*3 genotype, were evaluated. The final model was validated using normalized prediction distribution errors and bootstrapping. Results: A 2-compartment model with first-order absorption and elimination was used to describe TAC disposition. Population estimates of TAC, CL/F, apparent central distribution volume (V2/F), rate of absorption (Ka), and apparent peripheral distribution volume (V3/F) were 18.1 L/h (12%), 72.7 L (34%), 0.163 h−1 (17%), and 412 L (21%), respectively. The model and estimated parameters were found to be stable. Other covariates did not influence TAC CL/F. Both donor and recipient CYP3A5*1 genotypes were significantly correlated with TAC clearance, and CL/F was 1.70-fold higher in both donor and recipient CYP3A5*1 carriers than in noncarriers among Chinese liver transplant recipients. Conclusion and Relevance: A PPK model of TAC was established in Chinese adult liver transplantation recipients for starting-dose individualized medication, which can be expanded to optimize clinical efficacy and minimize toxicity with therapeutic drug monitoring.

Sign in / Sign up

Export Citation Format

Share Document